NEW YORK (GenomeWeb News) — The US Food and Drug Administration yesterday said it has cleared Agendia’s MammaPrint diagnostic for breast cancer recurrence.
 
The test is the first in vitro diagnostic multivariate index assay device approved by the agency since it released a draft guidance describing such products last year.
 
As GenomeWeb News reported last fall, IVDMIAs use mathematical formulas to interpret gene and protein data to guide medical decision-making, according to the draft guidance, which can be read here.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.